30 closest matches · ranked by relevance
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Melanoma
Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Melanoma
Primary: Recurrence-free Survival (RFS) - All Randomized Participants — NA; NA Months
Melanoma
Primary: Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) — NA; 36.9; 23.1; 15.4…
Malignant Melanoma
Primary: Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months — 38.6 percentage of participants
Stage IIIC Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma
Primary: Overall Survival (OS) — 20.4; 20.1 months — p=0.383
Recurrent Melanoma · Stage IA Skin Melanoma · Stage IB Skin Melanoma
Primary: Percentage of Participants With Successful Intravital Microscopy on Accessible Human Melanoma Tumors During Standard Local Excision — 70 percentage of participants
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Melanoma Stage Iii · Melanoma Stage Iv · Melanoma
Primary: The Antitumor Effect of Denosumab Alone as Represented by the Change in Recent Thymic Emigrant Cells in Peripheral Blood — 2.69; 2.42; 2.55; 1.92 number of cell per…
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Metastatic Melanoma · Recurrent Melanoma · Stage III Cutaneous Melanoma AJCC v7
Primary: Progression-free Survival — 6.9; 2.3 months — p=0.002
Clinical Stage III Cutaneous Melanoma AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Melanoma of Unknown Primary
Primary: Progression Free Survival — 2.7; 3.1 months — p=0.04
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Anti-tumor Response Defined as Either a CR, PR, or SD as Defined by RECIST — 1; 8; 6 participants
Melanoma
Primary: Pathologic Complete Response — 9 Participants
Melanoma
Primary: Number of Participants With Adverse Events — 6; 8; 0; 2 Participants
Metastatic Uveal Melanoma · Stage IV Uveal Melanoma AJCC v7
Primary: Overall Response Rate, Defined Per RECIST 1.1 — 1; 5; 11; 16 Participants
Melanoma
Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants
Cutaneous Melanoma · Mucosal Melanoma · Ocular Melanoma
Primary: Arm C: Number of Participants With the Pathologic Response Rate — 0; 0; 34 Participants
Melanoma
Primary: Best Objective Response Rate (BORR) — 24 percentage of patients
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Melanoma (Skin)
Primary: 9-week Progression-free Survival Rate — 0.44 proportion of patients
Melanoma
Primary: Association of Baseline C11-AMT PET SUV Max Value With Objective Response — 6; 6; 1; 13 Participants — p=0.08